This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Findings in Children With Brain Neoplasms and Hypopituitarism

Silva A. Arslanian, MD; Dorothy J. Becker, MBBCh, FCP(Paed); Peter A. Lee, MD, PhD; Allan L. Drash, MD; Thomas P. Foley, Jr, MD

Am J Dis Child. 1985;139(4):347-350.

Abstract
• We report the outcome of growth hormone (GH) therapy in 34 children (17 boys and 17 girls) with brain tumors in whom hypopituitarism developed. The types of tumors included the following: craniopharyngiomas (18); germinomas (four); astrocytomas (three); chromophobe adenomas (three); medulloblastomas (two); glioma (one); dermoid (one); retinoblastoma (one); and metastatic rhabdomyosarcoma from the pelvis (one). Ninety-four percent of the patients were GH deficient post–tumor therapy, which consisted of surgery with and without radiotherapy. Twenty-four of 34 patients received GH. Eight of 24 patients receiving GH had recurrence of tumor; 16 were tumor free eight to 72 months after initial therapy. Eleven patients had 12 recurrences. Patients with tumor recurrence had a considerably lower growth rate during the first year of GH therapy than those without recurrence (mean, 3.5 ± 1.3 cm/yr v 6.2 ± 2.5 cm/yr). Three of 11 patients with recurrence had not received GH therapy; however, one was receiving testosterone intramuscularly monthly at the time of a second recurrence. Thus, 24 of 34 patients with brain tumors and hypopituitarism received GH therapy. Eight (33%) of 24 had tumor recurrence, compared with three (30%) of ten who did not receive GH. The data suggest that GH therapy is probably not associated with increased rate of tumor recurrence.

(AJDC 1985;139:347-350)

Author Affiliations
From the Division of Endocrinology and Metabolism, Department of Pediatrics, School of Medicine, University of Pittsburgh.

Footnotes
Read before the annual meeting of the Society for Pediatric Research, San Francisco, May 3, 1984.

Reprint requests to Department of Pediatrics, Children's Hospital of Pittsburgh, 125 DeSoto St, Pittsburgh, PA 15213 (Dr Foley).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Expression and Growth Dependency of the Insulin-Like Growth Factor I Receptor in Craniopharyngioma Cells: A Novel Therapeutic Approach
Ulfarsson et al.
Clin. Cancer Res. 2005;11:4674-4680.
ABSTRACT | FULL TEXT  

Risk of Disease Recurrence and Second Neoplasms in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study
Sklar et al.
J. Clin. Endocrinol. Metab. 2002;87:3136-3141.
ABSTRACT | FULL TEXT  

Growth Hormone Treatment of Children with Brain Tumors and Risk of Tumor Recurrence
Swerdlow et al.
J. Clin. Endocrinol. Metab. 2000;85:4444-4449.
ABSTRACT | FULL TEXT